Aktienanalyse zu BioXcel Therapeutics Inc (BTAI)BTAIBioXcel Therapeutics Inc

BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Given the current price of $0.1814 and the recent bankruptcy filing, BioXcel Therapeutics is not a good buy right now. The stock has plummeted 77.43% in the last five days and has a very low RSI of 10.284, indicating extreme oversold conditions. The company's financial health is concerning, with a net income loss of $14.7 million in Q2 2026 and a gross margin of only 87.91%. The main risk is the ongoing bankruptcy proceedings, which could further dilute shareholder value.

4 analysts cover BTAI: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 5.50.